Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Product information and disease descriptionProduct descriptionProduct information

Special populations

9 evidence topics · 7 sources

Older adults: upper age limit and participants aged 65 years or older in the phase 3 trial
Age groupRAPIDe-3 enrolled participants (N = 134), n (%)
Aged 12 to younger than 18 years“10 (7.5)”
Aged 18 to younger than 65 years“116 (86.6)”
Aged 65 years or older“8 (6.0)”